Drug intelligence / Profile preview

TERT-101

Development stage: Preclinical
Lead developer: Rejuvenation Technologies
Modality: Small Molecules
Administration: Oral

Overview

**TERT-101** is a TERT modulator in early preclinical development for liver diseases, including liver cirrhosis. Developed by Rejuvenation Technologies, it targets telomerase reverse transcriptase (TERT), a catalytic subunit of telomerase overexpressed in most cancers and implicated in cellular immortality and disease processes. Its specific mechanism of action remains undisclosed, with global R&D status listed as pending.[11][13]

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on TERT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TERT-101.

Explore the full profile